Recombinant adeno-associated virus vector carrying the thrombomodulin lectin-like domain for the treatment of abdominal aortic aneurysm

doi:10.1016/j.atherosclerosis.2017.03.024

CNU IR > College of Sustainable Environment and Recreation > Dept. of Tourism Management > Periodical Articles > Item 310902800/31598

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31598

Title:	Recombinant adeno-associated virus vector carrying the thrombomodulin lectin-like domain for the treatment of abdominal aortic aneurysm
Authors:	Lai, Chao-Han Wang, Kuan-Chieh Kuo, Cheng-Hsiang Lee, Fang-Tzu Cheng, Tsung-Lin Chang, Bi-Ing Yang, Yu-Jen Shi, Guey-Yueh Wu, Hua-Lin
Contributors:	Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Dept Surg, Coll Med Natl Cheng Kung Univ, Coll Med, Cardiovasc Res Ctr Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med Chia Nan Univ Pharm & Sci, Dept Tourism Management, Coll Recreat & Hlth Management Kaohsiung Med Univ, Dept Physiol, Coll Med Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr
Keywords:	Adeno-associated virus Thrombomodulin Abdominal aortic aneurysm Receptor for advanced glycation end product High-mobility group box 1 Inflammation
Date:	2017-07
Issue Date:	2018-11-30 15:49:41 (UTC+8)
Publisher:	Elsevier Ireland Ltd
Abstract:	Background and aims: Thrombomodulin (TM), through its lectin-like domain (TMD1), sequesters proinflammatory high-mobility group box 1 (HMGB1) to prevent it from engaging the receptor for advanced glycation end product (RAGE) that sustains inflammation and tissue damage. Our previous study demonstrated that short-term treatment with recombinant TM containing all the extracellular domains (i.e., rTMD123) inhibits HMGB1-RAGE signaling and confers protection against CaCl2-induced AAA formation. In this study, we attempted to further optimize TM domains, as a potential therapeutic agent for AAA, using the recombinant adeno-associated virus (AAV) vector. Methods: The therapeutic effects of recombinant TMD1 (rTMD1) and recombinant AAV vectors carrying the lectin-like domain of TM (rAAV-TMD1) were evaluated in the CaCl2-induced AAA model and angiotensin II-infused AAA model, respectively. Results: In the CaCl2-induced model, treatment with rTMD1 suppressed the tissue levels of HMGB1 and RAGE, macrophage accumulation, elastin destruction and AAA formation, and the effects were comparable to a mole-equivalent dosage of rTMD123. In the angiotensin II-infused model, a single intravenous injection of rAAV-TMD1 (1011 genome copies), which resulted in a persistently high serum level of TMD1 for at least 12 weeks, effectively attenuated AAA formation with suppression of HMGB1 and RAGE levels and inhibition of proinflammatory cytokine production, macrophage accumulation, matrix metalloproteinase activities and oxidative stress in the aortic wall. Conclusions: These findings corroborate the therapeutic potential of the TM lectin-like domain in AAA. The attenuation of angiotensin II-infused AAA by one-time delivery of rAAV-TMD1 provides a proof-ofconcept validation of its application as potential gene therapy for aneurysm development. (C) 2017 Elsevier B.V. All rights reserved.
Relation:	Atherosclerosis, v.262, pp.62-70
Appears in Collections:	[Dept. of Tourism Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1425	View/Open

Loading...